This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In an interview, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, professor of practice, sciences, and health outcomes research at the University of Maryland, explored the evolving landscape of vaccine recommendations, emphasizing the critical role pharmacists play in guiding patients through complex medical information.
Experts discuss the recent dismissal of all 17 members of the Advisory Committee on Immunization Practices (ACIP), a panel that provides guidance to the CDC on vaccine recommendations. This abrupt change has raised significant concerns within the health care community about the potential impact on vaccine trust and public health policy.
Garofoli, PharmD, BCACP, CTTS, FAPhA Publication Article Drug Topics Journal Drug Topics May/June 2025 Volume 169 Issue 03 Pharmacy team members can help patients prepare for upcoming travels, ensuring they are up to date with the recommended vaccines for their locations. The first resource is the CDC’s Yellow Book.
With significant progress made in researchers’ understanding of dermatological diseases, a pathway has been made for the development of targeted vaccines, according to data published in Vaccines. 5 Throughout the past 10 years, development of vaccines for preventing skin diseases has made significant progress.
In an interview on vaccine recommendations, health care professionals expressed growing concerns about the changing landscape of medical information dissemination. Health care professionals emphasize patient education and reliable information in the evolving vaccine recommendation landscape.
link] Recent Videos Related Content Q&A: Expert Highlights Importance of Trusted Sources for Vaccine Information Ashley Gallagher ; Laura Knockel, PharmD, BCACP July 6th 2025 Article Health care professionals emphasize patient education and reliable information in the evolving vaccine recommendation landscape.
image credit: Drobot Dean / stock.adobe.com READ MORE: ACIP Votes to Expand RSV Vaccine Recommendation to Include Adults 50 Years and Older Along with older adults over 65, children too are deemed at risk of contracting respiratory illnesses; a risk that was significantly increased during the COVID-19 pandemic.
FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients Ashley Gallagher June 2nd 2025 Article The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.
Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.
One thing I’d like to mention: before our specialtypharmacy got involved, it was very difficult to treat these patients, because all the prior authorizations went through the office. You basically had secretaries or admins trying to manage this complex field with these specialty drugs. This is a chronic disease—not a quick fix.
In a vote of 5 to 1 on Thursday, members of the Advisory Committee on Immunization Practices (ACIP) voted to recommend against influenza vaccine containing the preservative thimerosal. The recommendations include all US adults as well as recommending pregnant women also receive a thimerosal-free vaccine for influenza.
Reimbursements are a lot better in vaccines than it is in just filling scripts. Since you're not making money filling prescriptions until the reimbursement issue is corrected, you've got to diversify your practice and take advantage of different revenue streams with clinical services. Medication therapy management services.
Pharmacy Technicians Could Enhance Public Health by Becoming ‘Vaccine Champions’ Killian Meara October 3rd 2024 Article Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.
The software integrates directly with existing pharmacy management systems and features adherence monitoring, vaccine registry integration, performance measure tracking, an administrative assistant powered by AI, and more.
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy (..)
FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients Ashley Gallagher June 2nd 2025 Article The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.
Vaccine Coverage Remains Low Among Forcibly Displaced Children Brian Nowosielski June 17th 2025 Article Researchers conducted a systematic review and meta-analysis to estimate vaccine coverage and identify factors associated with vaccination among forcibly displaced, pediatric populations.
Related Content Measles Outbreak Reaches Over 800 Confirmed Cases in the US Ashley Gallagher June 7th 2025 Article Building trust with patients through fact-based information could help boost vaccination rates to the desirable coverage. 2013;3(4):e002361. 2013;3(4):e002361.
She admitted she was using them for injection drug use, and I gave her 5 syringes we were using for COVID-19 vaccine injections that were provided by the government. She was most grateful and assured me she was going to seek help the next day.
The introduction of the human papillomavirus (HPV) vaccine marked a major turning point, contributing to nearly a 50% reduction in incidence rates and a 70% decrease in mortality since the 1950s.
Q&A: Prioritizing Pharmacy Technician Well-Being Killian Meara ; Taylor Watterson, PharmD, PhD June 20th 2025 Article Taylor Watterson, PharmD, PhD, discusses the primary contributors to stress or frustration among pharmacy technicians and how to fix them.
Measles Outbreak Reaches Over 800 Confirmed Cases in the US Ashley Gallagher June 7th 2025 Article Building trust with patients through fact-based information could help boost vaccination rates to the desirable coverage.
Within this expansive network, the neurology clinical pharmacy specialist serves a vital dual role. The position ensures continuous care coordination and medication oversight across the system’s specialtypharmacy and neurology practices. 1 Evidence from recent studies supports the effectiveness of this approach.
ACIP Votes to Expand RSV Vaccine Recommendation to Include Adults 50 Years and Older Ashley Gallagher April 17th 2025 Article Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.
Related Content Pharmacy Technicians Could Enhance Public Health by Becoming ‘Vaccine Champions’ Killian Meara October 3rd 2024 Article Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates. J Am Pharm Assoc (2003). 2025 May 9:102419. doi: 10.1016/j.japh.2025.102419.
Exclusion criteria included having a bleeding disorder or having received any vaccine or monoclonal antibody for the prevention of RSV. Patients were included if they were a healthy early or moderate pre-term infant or late pre-term or full-term infant.
Sweden’s move from the 13-valent pneumococcal conjugate vaccine (PCV13) to PCV10 in 2019 is most likely responsible for the uptick in pHUS cases because of changes in serotype coverage. In the US, recommendations are slightly different, with PCV13 being the safest and most effective pneumococcal vaccine for both children and adults.
This single-center, retrospective, observational study included data from electronic health records and specialtypharmacies from January 1, 2023, to June 1, 2024, with specialtypharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period. Subscribe Now!
Key exclusion criteria included prior receipt of an HIV vaccine, prior use of long-acting systemic PrEP therapy, or prior use of HIV postexposure prophylaxis therapy. Passport to Protection: Best Practices for Travel Vaccines in the Pharmacy Setting Gretchen K.
Kevin Cleveland, PharmD, professor at Idaho State University, explores the potential impacts of changes to the Advisory Committee on Immunization Practices (ACIP), highlighting concerns about shifting medical guidance and vaccine recommendations. Cleveland: So I'll start as a provider.
Investigators found that incorporating either the pneumococcal conjugate vaccine (PCV) 20 or PCV 15 and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) had an incremental budget impact of $6.5 2,3 In June 2024, the ACIP announced updates to the vaccine schedule to prevent invasive pneumococcal disease.
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza. Sign up today for our free Drug Topics newsletter. References 1. News release. Cidara Therapeutics. June 23, 2025. Accessed June 26, 2025.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content